NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

TriSalus Life Sciences, Inc. (TLSI) Stock Analysis

TriSalus Life Sciences, Inc. (TLSI) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TLSI

$3.67

+$0.01 (+0.27%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TLSI with… →

TLSI Key Statistics

As of Oct 21, 2026
Trading
Open
$3.68
Previous Close
$3.66
Day's Range
3.60–3.73
52-Week Range
2.20–7.95
Volume
79.06K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.47
Valuation
Market Cap
$225.98M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.01
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.22
Financials (FY)
Revenue (FY)
$45.15M+53.41%
Net Income (FY)
−$39.23M
Profit marginThe share of revenue left as profit after all costs and taxes.
−62.59%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
61.57M
1-Year Return
−28.60%
Dividend and dates
Earnings Date
November 10, 2026
Avg Volume
269.79K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TLSI closed at $3.67, −28.60% over 1 year.

TriSalus Life Sciences, Inc. (TLSI) has a market capitalization of $225.98M.

In fiscal 2025, TLSI reported revenue of $45.15M.

TLSI Stock Return by Calendar Year

TriSalus Life Sciences, Inc. (TLSI) return since Feb 2021: what $10,000 became

1 year
$10,000 $7,140
−28.60%
5 years
$10,000 $3,698
−63.02%
Since Feb 2021
$10,000 $3,489
−65.11%

If you had invested $10,000 in TriSalus Life Sciences, Inc. (TLSI) at the close on February 8, 2021, the earliest close on record here, it would have been worth $3,489 at the close on October 21, 2026: −65.11% in total, −16.88% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−47.42%
2025+39.32%
2024−40.71%
2023−15.75%
2022+1.52%
2021 (partial year)−6.08%

As of October 21, 2026.

TLSI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$45.15M−$39.23M−86.9%
2024$29.43M−$30.05M−102.1%
2023$18.51M−$59.36M−320.7%
2022$12.40M−$47.19M−380.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$45.15M$38.19M−$26.95M−$39.23M−86.9%
2024$29.43M$25.33M−$36.17M−$30.05M−102.1%
2023$18.51M$15.91M−$54.48M−$59.36M−320.7%
2022$12.40M$10.14M−$36.44M−$47.19M−380.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TLSI Valuation vs Medical Devices Median

Median of 145 stocks
MetricTLSIMedical Devices medianvs median
P/S ratio5.012.5398% above
Profit margin−62.59%−14.78%47.8 pts below

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

TriSalus Life Sciences, Inc. (TLSI) carries a market capitalisation of $225.98M. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 102.

Over the past 52 weeks the price has ranged from $2.20 to $7.95. The most recent close on file for TLSI is $3.67, dated October 21, 2026. That is +$0.01 (+0.27%) against the previous close. The latest close sits 66.82% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $45.15M. That is +53.41% against the prior fiscal year, when revenue was $29.43M. The same year closed with a net loss of $39.23M. The reported profit margin is −62.59%. That is 47.8 percentage points below the Medical Devices median of −14.78%. Trailing earnings per share are −1.22.

Across the 4 fiscal years on file, revenue moves from $12.40M in 2022 to $45.15M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 5.01. On price-to-sales that is 98.17% above the Medical Devices median of 2.53. 145 Medical Devices companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.47. Annualized volatility over the trailing 5 years is 61.72%. The trailing one-year total return is −28.60%. Across 5 years the annualized return works out at −18.04%.

Growth & Income

No dividend is on file for TLSI.

So far in 2026 the total return is −47.42%. The strongest complete calendar year on file is 2025 at +39.32%; the weakest is 2024 at −40.71%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

TriSalus Life Sciences, Inc. (TLSI) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
TriSalus Life Sciences, Inc. TLSI $225.98M —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. TriSalus Life Sciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Visit website →